A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT ID: NCT06841354
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
1000 participants
INTERVENTIONAL
2025-03-16
2030-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: Sacituzumab Tirumotecan
Participants receive sacituzumab tirumotecan intravenously (IV) at a dose of 4 mg/kg every 2 weeks (Q2W) until disease progression, toxicity or discontinuation.
Sacituzumab tirumotecan
IV Infusion
Rescue Medication
Participants receive the following pre-medications before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).
Arm B: Sacituzumab Tirumotecan + Pembrolizumab
Participants receive sacituzumab tirumotecan IV 4 mg/kg Q2W until disease progression, toxicity or discontinuation PLUS pembrolizumab IV 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to \~2 years).
Sacituzumab tirumotecan
IV Infusion
Pembrolizumab
IV Infusion
Rescue Medication
Participants receive the following pre-medications before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).
Arm C: Treatment of Physician's Choice (TPC)
Participants receive physician's choice of chemotherapy agent(s): paclitaxel IV 80 mg/m\^2 once every week (Q1W) OR paclitaxel IV 90 mg/m\^2 on Days 1, 8, and 15, every 4 weeks (Q4W) OR nab-paclitaxel IV 100 mg/m\^2 on Days 1, 8, and 15, Q4W OR gemcitabine IV 1000 mg/m\^2 on Days 1 and 8, every 3 weeks (Q3W) PLUS carboplatin IV area under the curve (AUC) 2 mg/mL/min on Days 1 and 8, Q3W, until disease progression, toxicity or discontinuation.
Paclitaxel
IV Infusion
Nab-paclitaxel
IV Infusion
Gemcitabine
IV Infusion
Carboplatin
IV Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab tirumotecan
IV Infusion
Pembrolizumab
IV Infusion
Rescue Medication
Participants receive the following pre-medications before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).
Paclitaxel
IV Infusion
Nab-paclitaxel
IV Infusion
Gemcitabine
IV Infusion
Carboplatin
IV Infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has not received systemic treatment for locally recurrent unresectable or metastatic breast cancer
* Participants previously treated for early-stage breast cancer must have completed all prior therapy for early-stage breast cancer with curative intent at least 6 months before the first disease recurrence
* Is a candidate for treatment with pembrolizumab and one of the TPC options: paclitaxel or nab-paclitaxel or gemcitabine + carboplatin
* Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline with the exception of alopecia or vitiligo. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
Exclusion Criteria
* Has TNBC with evaluable tumor programmed death ligand 1 (PD-L1) expression at combined positive score (CPS) ≥10
* Has received prior systemic therapy for treatment of locally recurrent unresectable or metastatic breast cancer
* Has Grade ≥2 peripheral neuropathy
* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
* Has skin only metastatic disease
* Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications
* Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Has known additional malignancy that is progressing or has required active treatment within the past 5 years
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable
* Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (HCV) (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection
* History of stem cell/solid organ transplant
* Has not adequately recovered from major surgery or has ongoing surgical complications
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USA Mitchell Cancer Institute ( Site 0090)
Mobile, Alabama, United States
Ironwood Cancer & Research Centers ( Site 0036)
Chandler, Arizona, United States
UCLA Department of Medicine - Hematology & Oncology ( Site 0047)
Los Angeles, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016)
San Francisco, California, United States
Yale New Haven Hospital ( Site 0001)
New Haven, Connecticut, United States
AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0007)
Altamonte Springs, Florida, United States
Florida Cancer Specialists - East ( Site 7000)
West Palm Beach, Florida, United States
University Cancer & Blood Center, LLC ( Site 0023)
Athens, Georgia, United States
St. Luke's Cancer Institute: Boise ( Site 0037)
Boise, Idaho, United States
University of Illinois Cancer Center ( Site 0044)
Chicago, Illinois, United States
MedStar Franklin Square Medical Center ( Site 0031)
Baltimore, Maryland, United States
MedStar Good Samaritan Hospital ( Site 0079)
Baltimore, Maryland, United States
MedStar Montgomery Medical Center ( Site 0078)
Olney, Maryland, United States
Holy Cross Hospital ( Site 0091)
Silver Spring, Maryland, United States
Allina Health Cancer Institute ( Site 0069)
Minneapolis, Minnesota, United States
Comprehensive Cancer Centers of Nevada ( Site 0015)
Las Vegas, Nevada, United States
Renown Regional Medical Center ( Site 0005)
Reno, Nevada, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0082)
Hackensack, New Jersey, United States
New Mexico Oncology Hematology Consultants Ltd. ( Site 0019)
Albuquerque, New Mexico, United States
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0073)
Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center ( Site 0003)
New York, New York, United States
UNC REX Cancer Center ( Site 0071)
Raleigh, North Carolina, United States
SCRI Oncology Partners ( Site 7004)
Nashville, Tennessee, United States
Texas Oncology - DFW ( Site 8007)
Dallas, Texas, United States
Texas Oncology - West Texas ( Site 8004)
El Paso, Texas, United States
Texas Oncology - San Antonio ( Site 8001)
San Antonio, Texas, United States
Virginia Oncology Associates (VOA) ( Site 8002)
Norfolk, Virginia, United States
Instituto de Investigaciones Clinicas Mar del Plata ( Site 2401)
Mar del Plata, Buenos Aires, Argentina
Instituto Alexander Fleming ( Site 2402)
Mar del Plata, Buenos Aires, Argentina
Hospital Italiano de Cordoba ( Site 2406)
Córdoba, Córdoba Province, Argentina
Clinica Viedma ( Site 2403)
Viedma, Río Negro Province, Argentina
Fundacion Estudios Clinicos ( Site 2405)
Rosario, Santa Fe Province, Argentina
Hospital Provincial del Centenario ( Site 2410)
Rosario, Santa Fe Province, Argentina
Fundacion Centro Oncologico de Integración Regional ( Site 2400)
Mendoza, , Argentina
Blacktown Hospital ( Site 5500)
Blacktown, New South Wales, Australia
Peninsula Health Frankston Hospital ( Site 5501)
Frankston, Victoria, Australia
ZAS Sint Augustinus ( Site 3102)
Antwerp, Flanders, Belgium
Ziekenhuis Oost Limburg ( Site 3105)
Genk, Limburg, Belgium
AZ Maria Middelares ( Site 3103)
Ghent, Oost-Vlaanderen, Belgium
UZ Gent ( Site 3101)
Ghent, Oost-Vlaanderen, Belgium
Hospital de Câncer de Recife ( Site 2300)
Recife, Pernambuco, Brazil
Liga Norte Riograndense Contra o Cancer ( Site 2310)
Natal, Rio Grande do Norte, Brazil
Hospital Nossa Senhora da Conceição ( Site 2302)
Porto Alegre, Rio Grande do Sul, Brazil
Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 2307)
Barretos, São Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 2301)
São Jose Do Rio Preto, São Paulo, Brazil
IBCC - Núcleo de Pesquisa e Ensino ( Site 2306)
São Paulo, , Brazil
Lakeridge Health ( Site 0217)
Oshawa, Ontario, Canada
North York General Hospital ( Site 0209)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0202)
Toronto, Ontario, Canada
CIUSSS- saguenay-Lac-Saint-Jean ( Site 0213)
Chicoutimi, Quebec, Canada
Centre Hospitalier de l'Université de Montréal ( Site 0208)
Montreal, Quebec, Canada
Jewish General Hospital ( Site 0203)
Montreal, Quebec, Canada
St. Marys Hospital Center ( Site 0201)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 0204)
Montreal, Quebec, Canada
Hopital Du Saint-Sacrement ( Site 0210)
Québec, Quebec, Canada
IC La Serena Research ( Site 2007)
La Serena, Coquimbo Region, Chile
FALP ( Site 2000)
Santiago, Region M. de Santiago, Chile
Clínica UC San Carlos de Apoquindo ( Site 2008)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 2001)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS ( Site 2005)
Viña del Mar, Región de Valparaíso, Chile
Biocenter ( Site 2009)
Concepción, Región del Biobío, Chile
The First Afflilated Hospital of Bengbu Medical College ( Site 5022)
Bengbu, Anhui, China
The First Affiliated Hospital of Chongqing Medical University ( Site 5039)
Chongqing, Chongqing Municipality, China
Chongqing University Three Gorges Hospital ( Site 5020)
Chongqing, Chongqing Municipality, China
The First Affiliated hospital of Xiamen University ( Site 5035)
Xiamen, Fujian, China
Sun Yat-Sen University Cancer Center ( Site 5014)
Guangzhou, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital. ( Site 5008)
Nanning, Guangxi, China
Henan Cancer Hospital ( Site 5001)
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical Science & Technology ( Site 5007)
Wuhan, Hubei, China
Xiangyang Central Hospital ( Site 5017)
Xiangyang, Hubei, China
Jiangsu Province Hospital ( Site 5009)
Nanjing, Jiangsu, China
Xuzhou Central Hospital ( Site 5036)
Xuzhou, Jiangsu, China
The First Hospital of Jilin University ( Site 5003)
Changchun, Jilin, China
The First Affiliated Hospital of Xi an Jiaotong University ( Site 5005)
Xi'an, Shaanxi, China
Jinan Central Hospital ( Site 5031)
Jinan, Shandong, China
LinYi Cancer Hospital ( Site 5021)
Linyi, Shandong, China
Sichuan Cancer Hospital. ( Site 5018)
Chengdu, Sichuan, China
The Second People's Hospital of Neijiang ( Site 5016)
Neijiang, Sichuan, China
Affiliated Tumor Hospital of Xinjiang Medical University ( Site 5006)
Ürümqi, Xinjiang, China
The First Affiliated Hospital Zhejiang University School of Medicine ( Site 5026)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 5012)
Hangzhou, Zhejiang, China
The Second Affiliated hospital of Zhejiang University school of medicine ( Site 5024)
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province ( Site 5029)
Linhai, Zhejiang, China
Instituto de Cancerología ( Site 2206)
Medellín, Antioquia, Colombia
Centro Cancerologico del Caribe LTD ( Site 2209)
Barranquilla, Atlántico, Colombia
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 2203)
Bogotá, Bogota D.C., Colombia
IMAT S.A.S ( Site 2202)
Montería, Departamento de Córdoba, Colombia
Oncologos Del Occidente ( Site 2208)
Pereira, Risaralda Department, Colombia
Masarykuv onkologicky ustav ( Site 3500)
Brno, South Moravian, Czechia
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 3301)
Helsinki, Uusimaa, Finland
CENTRE LEON BERARD ( Site 3004)
Lyon, Auvergne-Rhône-Alpes, France
Clinique Francois Chenieux ( Site 3006)
Limoges, Haute-Vienne, France
Institut Regional du Cancer Montpellier ( Site 3009)
Montpellier, Herault, France
Institut De Cancerologie De L Ouest ( Site 3003)
Saint-Herblain, Loire-Atlantique, France
Centre Henri Becquerel ( Site 3001)
Rouen, Seine-Maritime, France
HIA Sainte Anne ( Site 3007)
Toulon, Var, France
Hôpital Européen Georges Pompidou ( Site 3011)
Paris, , France
Caritas Klinikum Saarbruecken St. Theresia ( Site 4301)
Saarbrücken, Saarland, Germany
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterapias Klinika ( Site 3407)
Szeged, Csongrád megye, Hungary
Rambam Health Care Campus ( Site 3700)
Haifa, , Israel
Shaare Zedek Medical Center ( Site 3704)
Jerusalem, , Israel
Rabin Medical Center ( Site 3702)
Petah Tikva, , Israel
Sheba Medical Center ( Site 3701)
Ramat Gan, , Israel
Sourasky Medical Center ( Site 3703)
Tel Aviv, , Israel
Istituto Nazionale Tumori Regina Elena ( Site 4607)
Rome, Roma, Italy
Policlincio Gemelli ( Site 4602)
Roma, , Italy
Aichi Cancer Center ( Site 5117)
Nagoya, Aichi-ken, Japan
Nagoya City University Hospital ( Site 5108)
Nagoya, Aichi-ken, Japan
Hokkaido University Hospital ( Site 5100)
Sapporo, Hokkaido, Japan
Tokai University Hospital ( Site 5107)
Isehara, Kanagawa, Japan
Kanagawa Cancer Center ( Site 5106)
Yokohama, Kanagawa, Japan
Mie University Hospital ( Site 5109)
Tsu, Mie-ken, Japan
The University of Osaka Hospital ( Site 5111)
Suita, Osaka, Japan
Saitama Medical University International Medical Center ( Site 5116)
Hidaka, Saitama, Japan
Juntendo University Hospital ( Site 5104)
Bunkyo, Tokyo, Japan
Cancer Institute Hospital of JFCR ( Site 5102)
Koto, Tokyo, Japan
Showa Medical University Hospital ( Site 5103)
Shinagawa, Tokyo, Japan
National Center for Global Health and Medicine ( Site 5105)
Shinjuku, Tokyo, Japan
Akita University Hospital ( Site 5115)
Akita, , Japan
Fukushima Medical University Hospital ( Site 5101)
Fukushima, , Japan
Hiroshima City Hiroshima Citizens Hospital ( Site 5113)
Hiroshima, , Japan
Social medical corporation Hakuaikai Sagara Hospital ( Site 5114)
Kagoshima, , Japan
Kyoto University Hospital ( Site 5110)
Kyoto, , Japan
Okayama University Hospital ( Site 5118)
Okayama, , Japan
Osaka International Cancer Institute ( Site 5112)
Osaka, , Japan
National Cancer Institute ( Site 5401)
Putrajaya, Putrajaya, Malaysia
Sarawak General Hospital ( Site 5400)
Kuching, Sarawak, Malaysia
Pantai Hospital Kuala Lumpur ( Site 5402)
Kuala Lumpur, , Malaysia
University Malaya Medical Centre ( Site 5403)
Kuala Lumpur, , Malaysia
CIO - Centro de Inmuno-Oncología de Occidente ( Site 2504)
Guadalajara, Jalisco, Mexico
Grupo Médico ASSET ( Site 2507)
Mexico City, Mexico City, Mexico
Centro Oncologico de Alta Especialidad, S.C. ( Site 2509)
Mexico City, Mexico City, Mexico
Higiea Oncologia ( Site 2505)
Mexico City, Mexico City, Mexico
Oncare - Unidad Valle ( Site 2502)
San Pedro Garza García, Nuevo León, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 2503)
Oaxaca City, Oaxaca, Mexico
Centro de Investigación Oncológica Galerías SC ( Site 2511)
Aguascalientes, , Mexico
Unidad de Mastologia Avanzada de Chihuahua S.A de C.V ( Site 2510)
Chihuahua City, , Mexico
Centro Potosino de Investigación Médica ( Site 2512)
San Luis Potosí City, , Mexico
Ziekenhuis Rijnstate ( Site 4501)
Arnhem, Gelderland, Netherlands
Zuyderland Medical Centre ( Site 4507)
Sittard Geleen, Limburg, Netherlands
ETZ Elisabeth ( Site 4504)
Tilburg, North Brabant, Netherlands
Deventer Ziekenhuis ( Site 4503)
Deventer, Overijssel, Netherlands
Erasmus Medisch Centrum ( Site 4505)
Rotterdam, South Holland, Netherlands
Meander Medisch Centrum ( Site 4500)
Amersfoort, Utrecht, Netherlands
Harbour Cancer & Wellness ( Site 5600)
Newmarket, Auckland, New Zealand
Bowen Hospital ( Site 5601)
Wellington, , New Zealand
Clínica Internacional - Sede San Borja ( Site 2604)
Lima, , Peru
IPOR Instituto Peruano de Oncología & Radioterapia ( Site 2601)
Lima, , Peru
Oncosalud ( Site 2600)
Lima, , Peru
Hospital Militar Central Coronel Luis Arias Schereiber ( Site 2603)
Lima, , Peru
Wielkopolskie Centrum Onkologii-Oddział Onkologii Klinicznej i Immunoonkologii z Pododdziałem Dzien ( Site 3811)
Poznan, Greater Poland Voivodeship, Poland
Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 3802)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Pratia MCM Krakow ( Site 3812)
Krakow, Lesser Poland Voivodeship, Poland
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 3801)
Siedlce, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Piersi i Chirurgii ( Site 3803)
Warsaw, Masovian Voivodeship, Poland
Mazowiecki Szpital Onkologiczny ( Site 3807)
Wieliszew, Masovian Voivodeship, Poland
Szpitale Pomorskie Sp. z o. o. ( Site 3805)
Gdynia, Pomeranian Voivodeship, Poland
Szpital Wojewodzki im.M.Kopernika. ( Site 3800)
Koszalin, West Pomeranian Voivodeship, Poland
Institutul Oncologic Cluj ( Site 4701)
Cluj-Napoca, Cluj, Romania
S.C. Radiotherapy Center Cluj S.R.L ( Site 4705)
Comuna Floresti, Cluj, Romania
Centrul de Oncologie "Sfântul Nectarie" ( Site 4702)
Craiova, Dolj, Romania
Spitalul Municipal Schuller Ploiești ( Site 4707)
Ploieşti, Prahova, Romania
Cabinet Medical Oncomed ( Site 4704)
Timișoara, Timiș County, Romania
Spitalul Clinic Filantropia ( Site 4703)
Bucharest, , Romania
Centrul Medical Neolife- Baneasa ( Site 4706)
Bucharest, , Romania
National Cancer Center ( Site 5202)
Goyang-si, Kyonggi-do, South Korea
Seoul National University Bundang Hospital ( Site 5204)
Seongnam, Kyonggi-do, South Korea
Kyungpook National University Chilgok Hospital ( Site 5205)
Daegu, Kyongsangbuk-do, South Korea
Seoul National University Hospital ( Site 5200)
Seoul, , South Korea
Severance Hospital Yonsei University Health System ( Site 5201)
Seoul, , South Korea
Samsung Medical Center ( Site 5203)
Seoul, , South Korea
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 4104)
Seville, Andalusia, Spain
ICO L Hospitalet ( Site 4101)
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Clinico San Carlos ( Site 4100)
Madrid, Madrid, Comunidad de, Spain
Hospital General Universitario de Valencia ( Site 4102)
Valencia, Valenciana, Comunitat, Spain
Parc de Salut Mar - Hospital del Mar ( Site 4106)
Barcelona, , Spain
Hospital Beata María Ana ( Site 4105)
Madrid, , Spain
Hospital Universitario Ramon y Cajal ( Site 4103)
Madrid, , Spain
Taichung Veterans General Hospital ( Site 5303)
Taichung, , Taiwan
National Cheng Kung University Hospital ( Site 5304)
Tainan, , Taiwan
National Taiwan University Hospital ( Site 5300)
Taipei, , Taiwan
Mackay Memorial Hospital ( Site 5301)
Taipei, , Taiwan
Chang Gung Memorial Hospital ( Site 5302)
Taoyuan District, , Taiwan
Faculty of Medicine Siriraj Hospital ( Site 5800)
Bangkoknoi, Bangkok, Thailand
Songklanagarind hospital ( Site 5801)
Hat Yai, Changwat Songkhla, Thailand
Faculty of Medicine - Khon Kaen University ( Site 5802)
Khon Kaen, , Thailand
Royal Cornwall Hospital ( Site 4003)
Truro, Cornwall, United Kingdom
St Bartholomew's Hospital ( Site 4001)
London, London, City of, United Kingdom
University College London Hospital ( Site 4007)
London, London, City of, United Kingdom
Nottingham University Hospital NHS Trust ( Site 4009)
Nottingham, Nottinghamshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-2870-011
Identifier Type: OTHER
Identifier Source: secondary_id
TroFuse-011
Identifier Type: OTHER
Identifier Source: secondary_id
2024-516834-36-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1311-2310
Identifier Type: REGISTRY
Identifier Source: secondary_id
2870-011
Identifier Type: -
Identifier Source: org_study_id